Evidence map›Paper›PMID 37765006›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Synthesis, DFT Study, and In Vitro Evaluation of Antioxidant Properties and Cytotoxic and Cytoprotective Effects of New Hydrazones on SH-SY5Y Neuroblastoma Cell Lines.

Diana Tzankova, Hristina Kuteva, Emilio Mateev, Denitsa Stefanova, Alime Dzhemadan, Yordan Yordanov, Alexandrina Mateeva, Virginia Tzankova, Magdalena Kondeva-Burdina, Alexander Zlatkov and 1 more

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Diana TzankovaDepartment "Pharmaceutical Chemistry", Faculty of Pharmacy, Medical University-Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria.
Hristina KutevaLaboratory "Drug metabolism and Drug Toxicity", Department "Pharmacology, Pharmacotherapy and Toxicology", Faculty of Pharmacy, Medical University-Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria.
Emilio MateevDepartment "Pharmaceutical Chemistry", Faculty of Pharmacy, Medical University-Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria.ORCID 0000-0002-5885-7213
Denitsa StefanovaLaboratory "Drug metabolism and Drug Toxicity", Department "Pharmacology, Pharmacotherapy and Toxicology", Faculty of Pharmacy, Medical University-Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria.
Alime DzhemadanLaboratory "Drug metabolism and Drug Toxicity", Department "Pharmacology, Pharmacotherapy and Toxicology", Faculty of Pharmacy, Medical University-Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria.
Yordan YordanovLaboratory "Drug metabolism and Drug Toxicity", Department "Pharmacology, Pharmacotherapy and Toxicology", Faculty of Pharmacy, Medical University-Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria.ORCID 0000-0003-1029-9870
Alexandrina MateevaDepartment "Pharmaceutical Chemistry", Faculty of Pharmacy, Medical University-Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria.
Virginia TzankovaLaboratory "Drug metabolism and Drug Toxicity", Department "Pharmacology, Pharmacotherapy and Toxicology", Faculty of Pharmacy, Medical University-Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria.
Magdalena Kondeva-BurdinaLaboratory "Drug metabolism and Drug Toxicity", Department "Pharmacology, Pharmacotherapy and Toxicology", Faculty of Pharmacy, Medical University-Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria.
Alexander ZlatkovDepartment "Pharmaceutical Chemistry", Faculty of Pharmacy, Medical University-Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria.ORCID 0000-0002-1695-8454
Maya GeorgievaDepartment "Pharmaceutical Chemistry", Faculty of Pharmacy, Medical University-Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria.

Funding

European Union-NextGenerationEU, through the National Recovery and Resilience Plan of the Republic of Bulgaria BG-RRP-2.004-0004-C01
6 · The paper itself

Abstract

A series of ten new hydrazide-hydrazone derivatives bearing a pyrrole ring were synthesized and structurally elucidated through appropriate spectral characteristics. The target hydrazones were assessed for radical scavenging activity through 1,1-diphenyl-2-picrylhydrazyl (DPPH) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) tests, with ethyl 5-(4-bromophenyl)-1-(2-(2-(4-hydroxy-3,5-dimethoxybenzylidene)hydrazine-yl)-2-oxoethyl)-2-methyl-1H-pyrrole-3-carboxylate (

Indexed as

antioxidantcell protectioncellular toxicityDFTpyrroleSH-SY5Ysynthesis

Identifiers

PMID37765006
PMCPMC10537553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.